Relmada Therapeutics (RLMD US)
RLMD US$3.45
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 3.45
- Change
- ▲ 0.10 (2.84)
- Bid / Ask
- 2.93 - 3.74
- Volume
- 171,007
- Turnover
- 531,224
- Open
- 3.38
- Day Range
- 3.32 - 3.48
- VWAP
- 3.41
- Prev Close
- 3.35
- Last Trade
- 29/10 4:00pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 106,669,846
- NTA/Share
- 1.18
- Last Dividend
- —
- Dividend Ex Date
- —
- Dividend Pay Date
- —
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 0.00
- EBITDA
- -58.78
- Profit
- -57.39
- Earnings Per Share (EPS)
- -1.45
- Dividend Per Share (DPS)
- —
- Yield %
- 0.00
- Market Cap
- 367.48
- Price to Earnings Ratio (P/E)
- -3.79
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 0.00
- EBITDA
- —
- Profit
- -82.20
- Earnings Per Share (EPS)
- -0.61
- Dividend Per Share (DPS)
- —
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Undervalued
- Economic Moat
- None
- Financial Health
- Moderate
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 23 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 2.06 Fair value 4.25 One-star price 8.75
Morningstar Quantitative Rating as of 23 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 4.25
- Price / Fair Value
- 0.77
- Valuation
- Undervalued
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 23 OCT 2026. The slider runs from the five-star price (2.06) to the one-star price (8.75).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 3.27 |
| Price - 12 month high | 7.99 |
| Price - 12 month low | 2.07 |
| Pricing date | 22 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 1.77 |
| Market capitalization | 348.81 |
| 12 Month High price date | 6 MAY 2026 |
| 12 Month Low price date | 24 OCT 2025 |
| Volume - avg. trading volume for the last 3 months | 1.32 |
| Price - 1 Day % Change | -0.61% |
| Price - 13 week price percent change | -37.12% |
| Price - 26 week price percent change | -54.90% |
| Price - 5 Day % Change | 5.48% |
| Price - 52 week price percent change | 47.96% |
| Price - YTD price percent change | -27.81% |
| Price % Change Month To Date | -13.49% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | -1.450 |
| EPS excluding extraordinary items - trailing 12 month | -0.910 |
| EPS Normalized - most recent fiscal year | -1.079 |
| Revenue/share - most recent fiscal year | 0.000 |
| Revenue/share - trailing 12 month | 0.000 |
| Book value per share - most recent fiscal year | 1.180 |
| Book value per share - most recent quarter | 1.936 |
| Book value (tangible) per share - most recent fiscal year | 1.180 |
| Book value (tangible) per share - most recent quarter | 1.936 |
| Cash per share - most recent fiscal year | 0.048 |
| Cash per share - most recent quarter | 0.106 |
| Cash Flow per share - most recent fiscal year | -1.060 |
| Cash Flow per share - trailing 12 month | -0.648 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.000 |
| EBITD per share - trailing 12 month | -0.899 |
| EPS Basic excluding extraordinary items - most recent fiscal year | -1.450 |
| EPS Basic excluding extraordinary items - trailing 12 month | -0.910 |
| EPS including extraordinary items - most recent fiscal year | -1.450 |
| EPS including extraordinary items - trailing 12 month | -0.910 |
| Free Cash Flow per share - trailing 12 month | -0.648 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | — |
| P/E Normalized, most recent fiscal year | — |
| Price to sales - most recent fiscal year | — |
| Price to Tangible Book - most fiscal year | 1.69 |
| Price to Free Cash Flow per Share - most recent fiscal year | — |
| Price to Cash Flow per share - trailing 12 month | — |
| Price to Book - most recent fiscal year | 1.69 |
| P/E excluding extraordinary items high, trailing 12 months | — |
| P/E excluding extraordinary items low, trailing 12 months | — |
| Net Debt, LFI | -217.73 |
| Net Debt, LFY | -93.01 |
| Dividend Yield - 5 Year Average | — |
| Dividend Yield - indicated annual dividend divided by closing price | — |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.00% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | -41.84 |
| LT debt/equity - most recent fiscal year | 0.00% |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | 0.00% |
| LT debt/equity - most recent quarter | 0.00% |
| Total debt/total equity - most recent quarter | 0.00% |
| Free Cash Flow - trailing 12 month | -47.45 |
| Payout ratio - trailing 12 month | — |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 0.00 |
| Revenue - trailing 12 month | 0.00 |
| EBITD - most recent fiscal year | -58.78 |
| EBITD - trailing 12 month | -65.82 |
| Earnings before taxes - most recent fiscal year | -57.39 |
| Earnings before taxes - trailing 12 month | -61.93 |
| Net Income available to common - most recent fiscal year | -57.39 |
| Net Income available to common - trailing 12 months | -61.93 |
| Earnings before taxes Normalized - most recent fiscal year | -42.74 |
| Net Income Available to Common, Normalized - most recent fiscal year | — |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | -0.72 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | — |
| Net Profit Margin % - trailing 12 month | — |
| Operating margin - 1st historical fiscal year | — |
| Operating margin - trailing 12 month | — |
| Pretax margin - trailing 12 month | — |
| Pretax margin - 1st historical fiscal year | — |
| Operating Margin - 5 year average | — |
| Pretax Margin - 5 year average | — |
| Free Operating Cash Flow/Revenue, 5 Year Average | — |
| Free Operating Cash Flow/Revenue, TTM | — |
| Net Profit Margin - 5 year average | — |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | -141.00% |
| Return on average assets - trailing 12 month | -52.98% |
| Return on average equity - most recent fiscal year | -168.89% |
| Return on average equity - trailing 12 month | -57.64% |
| Return on average assets - 5 year average | -98.87% |
| Return on average equity - 5 year average | -113.26% |
| Net Income/employee - most recent fiscal year | -3,375,597.82 |
| Revenue/employee - most recent fiscal year | 0.00 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 0.00% |
| EPS growth rate, 5 year | — |
| Growth rate% - dividend, 3 year | — |
| Revenue/share (5 yr growth) | 0.00% |
| Growth rate% - Revenue, 3 year | 0.00% |
| Growth rate% - EPS, 3 year | — |
| Book value per share growth rate, 5 year | -28.84% |
| Capital Spending growth rate, 5 year | — |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | — |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
